A Follow-Up Study of Long-Term Efficacy of Patients with HER2-Positive Early Breast Cancer Who Had Been Enrolled in Study CT-P6 3.2
Latest Information Update: 11 Mar 2023
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors Celltrion
- 07 Mar 2023 Results (N=216) assessing comparable long-term efficacy of CT-P6 and reference trastuzumab in patients with HER2-positive early breast cancer, published in the BioDrugs.
- 22 Jul 2022 This trial has been completed in Romania(End Date: 18 Jan 2022), according to European Clinical Trials Database record.
- 13 May 2022 This trial has been completed in Poland (End Date: 18 Jan 2022), according to European Clinical Trials Database record.